Trinity Biotech plc Sponsored ADR
Trinity Biotech is a science and technology company specializing in high-quality laboratory and point-of-care diagnostics.
Investor website: https://trinitybiotech.com/
About
Trinity Biotech is a science and technology company specializing in high-quality laboratory and point-of-care diagnostics. The company is transitioning to explore advanced measurement, analytical science, and data-driven systems, aiming to bridge the physical-to-digital gap in an AI-driven world. With decades of experience, Trinity Biotech has developed trusted diagnostic solutions and is expanding into higher-value platforms that integrate complex physical signals into actionable digital insights. Their product portfolio includes FDA-cleared analyzers and rapid tests for various medical conditions, reflecting their expertise in regulated assay development and global commercialization.
Verified company data
- Leadership
- John Gillard (CEO, Joined Trinity Biotech in November 2020 as CFO and Secretary to the Board. Appointed CEO and President in December 2023. Chartered Accountant and Chartered Tax Advisor with experience at Alphabet Inc./Google and ION Investment Group.), Ronan O’Caoimh (Director, Co-founded Trinity Biotech in June 1992 and served as CFO until March 1994, then as CEO until October 2022. Former Managing Director of Noctech Limited.), Andrew Omidvar Ph.D., MBA (Director, Joined the Board in December 2023 with over 25 years of experience in technology solutions in various industries. Former Vice President of Government R&D and Enterprise for Philips.), Paul Tivnan (Director, Over 25 years of leadership experience in finance and corporate governance. Currently CFO of Deriva Energy LLC and has held CFO roles at Brookfield Renewable Ireland and Ardmore Shipping Corporation.)
Verified data last updated:
Recent filings
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-07-22_11-02-17.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-07-22_11-00-19.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-07-02_11-30-05.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-06-30_12-00-20.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-06-29_18-53-11.pdf
- Prospectus [Rule 424(b)(3)] · trib_2026-06-23_10-42-08.pdf
- Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 · trib_2026-06-23_10-39-44.pdf
- Prospectus [Rule 424(b)(3)] · trib_2026-06-18_19-50-12.pdf